Induction of HER2 immunity in outbred domestic cats by DNA electrovaccination

Cancer Immunology Research

Volumn 3, Issue 7, 2015, Pages 777-786

  Gibson, Heather M ^a   Veenstra, Jesse J ^a   Jones, Richard ^a   Vaishampayan, Ulka ^a   Sauerbrey, Michele ^b   Bepler, Gerold ^a   Lum, Lawrence ^a   Reyes, Joyce ^a   Weise, Amy ^a   Wei, Wei Zen ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oakland Veterinary Referral Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GROWTH FACTOR RECEPTOR; HER1 PROTEIN; HER3 PROTEIN; LAPATINIB; PROTEIN KINASE B; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN;

3T3 CELL LINE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; DOMESTIC CAT; ELECTROPORATION; HETEROLOGOUS EXPRESSION; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOLOGICAL TOLERANCE; MOUSE; MUTANT; MUTANT CAT; NONHUMAN; OUTBRED STRAIN; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BEAR; CAT; CELL PROLIFERATION; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; RAT; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CATS; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTROPORATION; FEMALE; HUMANS; IMMUNE TOLERANCE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; RATS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; URSIDAE; VACCINES, DNA;

EID: 84961944281     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0175     Document Type: Article

References (50)

1. Davis MM. A prescription for human immunology. Immunity 2008;29:835-8.
2. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy, and cancer vaccines. Curr Opin Immunol 2004;16:143-50.
3. Gendler SJ, Mukherjee P. Spontaneous adenocarcinoma mouse models for immunotherapy. Trends Mol Med 2001;7:471-5.
4. Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, et al. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010;70:119-28.
5. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-94.
6. Radkevich-Brown O, Jacob J, Kershaw M, Wei WZ. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res 2009;69:212-8.
7. Mullikin JC, Hansen NF, Shen L, Ebling H, Donahue WF, Tao W, et al. Light whole genome sequence for SNP discovery across domestic cat breeds. BMC Genomics 2010;11:406.
8. Available from: http://www.humanesociety.org/issues/pet-overpopulation/facts/pet-ownership-statistics.html
9. Pontius JU, Mullikin JC, Smith DR, Agencourt Sequencing T, Lindblad-Toh K, Gnerre S, et al. Initial sequence and comparative analysis of the cat genome. Genome Res 2007;17:1675-89.
10. O'Brien SJ, Menotti-Raymond M, Murphy WJ, Yuhki N. The Feline Genome Project. Ann Rev Genetics 2002;36:657-86.
11. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968;40:307-18.
12. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969;43:1249-61.
13. Hayden DW, Nielsen SW. Feline mammary tumours. J Small Anim Pract 1971;12:687-98.
14. Munson L, Moresco A. Comparative pathology ofmammary gland cancers in domestic and wild animals. Breast Dis 2007;28:7-21.
15. Gimenez F, Hecht S, Craig LE, Legendre AM. Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg 2010;12:214-24.
16. Overley B, Shofer FS, Goldschmidt MH, Sherer D, Sorenmo KU. Association between ovarihysterectomy and feline mammary carcinoma. J Vet Intern Med 2005;19:560-3.
17. Soares M, Correia J, Rodrigues P, Simoes M, de Matos A, Ferreira F. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microsc Microanal 2013;19:876-82.
18. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, et al. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005;65:907-12.
19. Ordas J, Millan Y, Dios R, Reymundo C, de Las Mulas JM. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007;7:179.
20. Winston J, Craft DM, Scase TJ, Bergman PJ. Immunohistochemical detection of HER-2/neu expression in spontaneous feline mammary tumours. Vet Comp Oncol 2005;3:8-15.
21. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, et al. Spontaneous felinemammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010;10:156.
22. Maniscalco L, Iussich S, de Las Mulas JM, Millan Y, Biolatti B, Sasaki N, et al. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J 2012;191:65-71.
23. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005;42:30-4.
24. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V. An Immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 2011;144:170-9.
25. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011;72:1631-8.
26. Manley CA, Leibman NF, Wolchok JD, Riviere IC, Bartido S, Craft DM, et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 2011;25:94-9.
27. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75:4040-7.
28. Traxler GS, Anderson E, LaPatra SE, Richard J, Shewmaker B, Kurath G. Naked DNA vaccination of Atlantic salmon Salmo salar against IHNV. Dis Aquat Organ 1999;38:183-90.
29. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene ther 2009;20:1269-78.
30. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra38.
31. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013;4:354.
32. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013;2:e23803.
33. Grunwald T, Tenbusch M, Schulte R, Raue K, Wolf H, Hannaman D, et al. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in non-human primates. J Virol 2014;88:3997-4007.
34. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genetics 2008;9:776-88.
35. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010;8:53.
36. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, et al. Protection against mammary tumor growth by vaccination with fulllength, modified human ErbB-2 DNA. Int J Cancer 1999;81:748-54.
37. Whittington PJ, Piechocki MP, Heng HH, Jacob JB, Jones RF, Back JB, et al. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res 2008;68:7502-11.
38. Diaz CM, Chiappori A, Aurisicchio L, Bagchi A, Clark J, Dubey S, et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med 2013;11:62.
39. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70:2604-12.
40. Minke JM, Schuuring E, van den Berghe R, Stolwijk JA, Boonstra J, Cornelisse C, et al. Isolation of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. Cancer Res 1991;51:4028-37.
41. Modiano JF, Kokai Y, Weiner DB, Pykett MJ, Nowell PC, Lyttle CR. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. J Cell Biochem 1991;45:196-206.
42. Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006;240:96-106.
43. Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J Invest Dermatol 2013;133:249-57.
44. Gibson H, Munns S, Freytag S, Barton K, Veenstra J, Bettahi I, et al. Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. Oncoimmunology 2015;4:e984523.
45. Gostring L, Malm M, Hoiden-Guthenberg I, Frejd FY, Stahl S, Lofblom J, et al. Cellular effects of HER3-specific affibody molecules. PloS ONE 2012;7:e40023.
46. McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe KL, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989;4:543-8.
47. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 1991;88:8691-5.
48. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
49. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984;312:545-8.
50. Jacob JB, Kong YC, Meroueh C, Snower DP, David CS, Ho YS, et al. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res 2007;67:7020-7.